{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"}],"units":"Participants"}],"description":"The percent of pts with confirmed ODC (CR, CCR, PR and SD90) based on OPDREC was summarized.","groups":[{"description":"Regimen was 14 mg/m2 IV over a 4-hour period on Days 1, 8, and 15 of a 28-day cycle. The protocol included 6 cycles of treatment; responding patients and patients who achieved at least Stable Disease (SD) had the option of continuing treatment beyond 6 cycles at the discretion of the Investigator and based on local regulations.","id":"OG000","title":"Romidepsin"}],"paramType":"NUMBER","populationDescription":"Efficacy analysis based on interim analysis of data for as treated population","reportingStatus":"POSTED","timeFrame":"Up to 10 months","title":"Percent of Pts With Objective Disease Control","type":"SECONDARY","unitOfMeasure":"Percent of participants"}